Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 245

1.

Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of head-to-head randomized controlled trials.

Romanelli RJ, Wu FM, Gamba R, Mojtabai R, Segal JB.

Depress Anxiety. 2014 Aug;31(8):641-52. doi: 10.1002/da.22232. Epub 2014 Jan 3. Review.

PMID:
24390912
2.

A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.

Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, Vermes D, Schmidt AB, Hembree E, Franklin M, Campeas R, Hahn CG, Petkova E.

Am J Psychiatry. 2008 May;165(5):621-30. doi: 10.1176/appi.ajp.2007.07091440. Epub 2008 Mar 3.

3.

Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder.

Foa EB, Simpson HB, Liebowitz MR, Powers MB, Rosenfield D, Cahill SP, Campeas R, Franklin M, Hahn CG, Hembree EA, Huppert JD, Schmidt AB, Vermes D, Williams MT.

J Clin Psychiatry. 2013 May;74(5):464-9. doi: 10.4088/JCP.12m08017.

4.

Standard individual cognitive behaviour therapy for paediatric obsessive-compulsive disorder: a systematic review of effect estimates across comparisons.

Skarphedinsson G, Hanssen-Bauer K, Kornør H, Heiervang ER, Landrø NI, Axelsdottir B, Biedilæ S, Ivarsson T.

Nord J Psychiatry. 2015 Feb;69(2):81-92. doi: 10.3109/08039488.2014.941395. Epub 2014 Aug 21. Review.

PMID:
25142430
5.

Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.

Dold M, Aigner M, Lanzenberger R, Kasper S.

Int J Neuropsychopharmacol. 2013 Apr;16(3):557-74. doi: 10.1017/S1461145712000740. Epub 2012 Aug 29. Review.

PMID:
22932229
6.

Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J Jr, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R.

JAMA Psychiatry. 2013 Nov;70(11):1190-9. doi: 10.1001/jamapsychiatry.2013.1932.

7.

Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.

Simpson HB, Gorfinkle KS, Liebowitz MR.

J Clin Psychiatry. 1999 Sep;60(9):584-90.

PMID:
10520976
8.

Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD).

Soomro GM, Altman D, Rajagopal S, Oakley-Browne M.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD001765. doi: 10.1002/14651858.CD001765.pub3. Review.

PMID:
18253995
9.

The place of and evidence for serotonin reuptake inhibitors (SRIs) for obsessive compulsive disorder (OCD) in children and adolescents: Views based on a systematic review and meta-analysis.

Ivarsson T, Skarphedinsson G, Kornør H, Axelsdottir B, Biedilæ S, Heyman I, Asbahr F, Thomsen PH, Fineberg N, March J; Accreditation Task Force of The Canadian Institute for Obsessive Compulsive Disorders.

Psychiatry Res. 2015 May 30;227(1):93-103. doi: 10.1016/j.psychres.2015.01.015. Epub 2015 Jan 28. Review.

PMID:
25769521
10.

Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis.

Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ, Henk HJ.

Psychopharmacology (Berl). 1998 Apr;136(3):205-16.

PMID:
9566805
11.

[Cognitive-behavior therapy for obsessive-compulsive disorder: a systematic review of the last decade].

Prazeres AM, Souza WF, Fontenelle LF.

Rev Bras Psiquiatr. 2007 Sep;29(3):262-70. Epub 2007 Sep 18. Review. Portuguese.

12.

Issues in the pharmacological treatment of obsessive-compulsive disorder.

Math SB, Janardhan Reddy YC.

Int J Clin Pract. 2007 Jul;61(7):1188-97. Epub 2007 May 18. Review.

PMID:
17511795
13.

Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.

Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, Huppert JD, Kjernisted K, Rowan V, Schmidt AB, Simpson HB, Tu X.

Am J Psychiatry. 2005 Jan;162(1):151-61.

PMID:
15625214
14.

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.

Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF.

Mol Psychiatry. 2006 Jul;11(7):622-32. Epub 2006 Apr 4. Review. Erratum in: Mol Psychiatry. 2006 Aug;11(8):795.

PMID:
16585942
15.

Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.

Storch EA, Goddard AW, Grant JE, De Nadai AS, Goodman WK, Mutch PJ, Medlock C, Odlaug B, McDougle CJ, Murphy TK.

J Clin Psychiatry. 2013 Jun;74(6):e527-32. doi: 10.4088/JCP.12m08278.

PMID:
23842022
16.

Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy.

Alonso P, Menchon JM, Pifarre J, Mataix-Cols D, Torres L, Salgado P, Vallejo J.

J Clin Psychiatry. 2001 Jul;62(7):535-40.

PMID:
11488364
17.

Cognitive-behavioral treatment of pediatric obsessive-compulsive disorder: an open clinical trial.

Franklin ME, Kozak MJ, Cashman LA, Coles ME, Rheingold AA, Foa EB.

J Am Acad Child Adolesc Psychiatry. 1998 Apr;37(4):412-9.

PMID:
9549962
18.

[Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials].

Dold M, Aigner M, Lanzenberger R, Kasper S.

Fortschr Neurol Psychiatr. 2011 Aug;79(8):453-66. doi: 10.1055/s-0031-1273397. Epub 2011 Aug 1. Review. German.

PMID:
21809258
19.

Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: is response to treatment predictable?

Carey PD, Lochner C, Kidd M, Van Ameringen M, Stein DJ, Denys D.

Int Clin Psychopharmacol. 2012 Nov;27(6):321-5.

PMID:
22859064
20.

Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.

Franklin ME, Sapyta J, Freeman JB, Khanna M, Compton S, Almirall D, Moore P, Choate-Summers M, Garcia A, Edson AL, Foa EB, March JS.

JAMA. 2011 Sep 21;306(11):1224-32. doi: 10.1001/jama.2011.1344. Erratum in: JAMA. 2012 Apr 25;307(16):1694.

Supplemental Content

Support Center